BACKGROUND
Total intravenous anesthesia (TIVA) is defined as induction and maintenance of general anesthesia using solely intravenous agents, which usually includes propofol and a short-acting opiate (e.g., fentanyl or remifentanil). Traditional inhalational anesthesia (IA) is maintenance of general anesthesia using inhalation agents (e.g., isoflurane or sevoflurane). Several studies have tried to assess the impact of TIVA in endoscopic sinus surgery (ESS) by evaluating the surgical field visibility score, mean arterial pressure, heart rate, operative time, and blood loss. Although some studies show TIVA reduces surgical blood loss when compared to traditional IA, other studies have shown no difference in blood loss. In our review, we will focus on the relationship between TIVA and intraoperative blood loss in ESS. Accurate measurements of estimated blood loss (EBL) in sinus surgery are difficult because of copious irrigation, blood lost to ingestion, and blood outside the surgical field. Furthermore, surgical time can affect EBL, such that blood loss at a constant rate would yield higher EBL for longer cases. To account for this, some studies calculate blood loss as a rate, yielding outcomes in blood loss per hour. Methods of calculating EBL vary between studies, but usually involve subtracting the volume of irrigation used from the total volume in the suction canisters.
1 To obtain the blood loss rate the EBL is divided by surgical time in hours. 2 
LITERATURE REVIEW
A prospective, randomized, controlled study Ankichetty et al. 3 (level 1b) included 40 patients, (20 TIVA and 20 IA patients). They reported no difference in blood loss between TIVA and IA (132.5 6 92.15 vs. 109 6 82.96, P 5 .34). The operative field conditions in both groups achieved a score of three or less on the six-point surgical field grading system (P 5 .34). The main differences noted were in the IA (isoflurane) group requiring increased fentanyl (P 5 .026) and having an overall longer procedure time (P 5 .01).
Eberhart et al. 4 (level 1b) designed a prospective, randomized, controlled trial with a total of 88 patients. The TIVA group (N 5 45) received propofol with remifentanil, whereas the IA group (N 5 43) received isoflurane with alfentanil. Mean arterial pressure (MAP) was maintained between 60 and 70 mm Hg. Although there was a trend toward reduced blood loss in the TIVA group, the difference was not statistically significant (P 5 .12).
Milonski et al. 5 (level 1b) assessed 90 patients in three groups (30 patients each). Groups I and II both received IA with sevoflurane for sedation and fentanyl in group I, remifentanil in group II. Group III received TIVA with propofol for sedation and remifentanil for analgesia. Controlled hypotension was applied to maintain the systolic blood pressure below 100 mm Hg, with analgesic and sedatives accordingly. Mean blood loss was significantly lower in group III compared to groups I and II (p < 0.01; coefficient of determination, R 2 5 15.7%); no significant differences between groups I and II were observed for this variable. Mean blood loss during surgery was 365.0 6 176.2, 340.0 6 150.5, and 225.0 6 91.7 mL, with a mean blood loss rate of 5.1 6 2.4, 4.5 6 2.2, and 3.4 6 1.1 mL/min in groups I, II, and III, respectively. The rate of blood loss/minute was significantly lower in group III versus groups I and II (P 5 .005; coefficient of determination, R 2 5 11.6 %). These findings suggest TIVA with propofol/remifentanil in the setting of controlled hypotension has reduced blood loss compared to IA with sevoflurane and either fentanyl or remifentanil. 5 In 2013, a prospective, randomized study of 33 patients by Chabaan et al. 2 (level 1b) calculated the mean blood loss per hour during ESS in 18 patients receiving TIVA with propofol and 15 patients receiving IA with sevoflurane. The patients' MAP was maintained at 70 to 80 mm Hg in both groups. In the TIVA group, the rate of blood loss was 78.5 6 14 mL/hr, whereas in the IA group it was 80.3 6 17 mL/hr (P 5 .93). The study did not show any difference in blood loss and surgical conditions between the TIVA and IA groups. Furthermore, Chabaan et al. noted that controlled hypotension has been associated with increased morbidity and mortality, and they state that there is good evidence that decreasing the MAP below 70 mm Hg can even increase intraoperative bleeding owing to local arteriolar vasodilation.
A systemic review by DeConde et al. 1 included nine randomized controlled trials (level 1a) comparing TIVA to IA in ESS from 1950 to 2012. Only six studies reported estimated blood loss for a total of 300 patients (154 received TIVA and 146 received IA). Two of these six studies are included in more detail in this review. 3, 4 However, all of the six studies used TIVA with propofol, whereas IA used either isoflurane or sevoflurane. Although these studies had heterogeneous variables and outcomes, the authors concluded that there is no significant difference in blood loss between TIVA and IA (103.4 6 23.3 vs 164.7 6 20.4, P 5 .1466. 1 
BEST PRACTICE
Most studies conclude that TIVA does not significantly reduce blood loss in ESS, when compared to IA.
The current literature supporting TIVA is limited to inconsistently controlled and reported studies. 1 However, we should be cautious in stating that all types of TIVA do not offer reduction in blood loss. This caution is justified by the fact that there are different agents used in TIVA, which may affect EBL outcomes. Hence, further studies are required to address these issues. Furthermore, other factors such as nasal polyposis, severity of the inflammatory disease, mean heart rate, blood pressure control, patient positioning, warm irrigation, topical decongestion, and epinephrine injection may play a significant role in blood loss and may not have been rigorously controlled in these studies. However, based on the available evidence, it does not appear that TIVA anesthesia provides any appreciable reduction in intraoperative blood loss when compared to standard general anesthesia protocols.
LEVEL OF EVIDENCE
The included studies are randomized, controlled studies with level of evidence ranging from 1a to 1b.
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